Skip to main content
SpringerLink
Log in

Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Havla JB, Pellkofer HL, Meinl I et al (2012) Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol 69:262–264

    Article  PubMed  Google Scholar 

  2. Hakiki B, Portaccio E, Giannini M et al (2012) Withdrawal of fingolimod treatment for relapsing–remitting multiple sclerosis: report of six cases. Mult Scler. doi:10.1177/1352458512454773

  3. Gross CM, Baumgartner A, Rauer S, Stich O (2012) Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology. [Epub ahead of print]

  4. Kappos L, Radue EW, O’Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401

    Article  PubMed  CAS  Google Scholar 

  5. Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415

    Article  PubMed  CAS  Google Scholar 

  6. Rovaris M, Confavreux C, Furlan R et al (2006) Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5:343–354

    Article  PubMed  Google Scholar 

  7. Miravalle A, Jensen R, Kinkel P (2011) Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 68(2):186–191

    Article  PubMed  Google Scholar 

  8. Ingwersen J, Aktas O, Kuery P et al (2011) Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol. doi:10.1016/j.clim.2011.05.005

    PubMed  Google Scholar 

  9. Yednock TA, Cannon C, Fritz LC et al (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha4beta1 integrin. Nature 356:63–66

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

Dr. Ghezzi has served on scientific advisory boards for Merck Serono, Biogen Idec Teva Pharmaceutical Industries Ltd.; has received speaker honoraria from Merck Serono, Biogen Idec, Bayer Schering Pharma, and Novartis, Serono Symposia International; served as a consultant for Novartis; and receives research support from Sanofi-Aventis, Biogen Idec, and Merck Serono. Dr. Rocca has served as consultant to Bayer Schering Pharma; received speakers’ bureaus for Biogen-Dompé and receives research support from Italian Ministry of Health. Prof. Filippi serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd. and Genmab A/S; has received funding for travel from Bayer Schering Pharma, Biogen-Dompè, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; serves as a consultant to Bayer Schering Pharma, Biogen-Dompè, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; serves on speakers’ bureaus for Bayer Schering Pharma, Biogen-Dompè, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; and receives research support from Bayer Schering Pharma, Biogen-Dompè, Genmab A/S, Merck Serono, Teva Pharmaceutical Industries Ltd. and Fondazione Italiana Sclerosi Multipla. Prof. Comi has served on scientific advisory boards for Bayer Schering Pharma, Merck Serono, Teva Pharmaceutical Industries Ltd., Sanofi-Aventis, Novartis, and Biogen Idec; has received speaker honoraria from Teva Pharmaceutical Industries Ltd., Sanofi-Aventis, Serono Symposia International, Foundation, Biogen Idec, Merck Serono, Novartis, and Bayer Schering Pharma. Dr. Zaffaroni has served on scientific advisory boards for Teva, Medtronics, Merck Serono and Novartis, and served as a consultant for Biogen Idec. Dr. Annovazzi has served as consultant to Biogen-Dompè and Teva Pharmaceuticals and received speaker’s bureaus for Biogen-Dompè. Dr. Baroncini and Dr. Minonzio report no disclosures.

Ethical standard

This study has been approved by the appropriate ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

Author information

Authors and Affiliations

  1. Multiple Sclerosis Study Center, Hospital of Gallarate, Gallarate, Italy

    A. Ghezzi, D. Baroncini, P. Annovazzi & M. Zaffaroni

  2. Neuroimaging Research Unit, Division of Neuroscience, Institute of Experimental Neurology, Hospital S. Raffaele, Milan, Italy

    M. A. Rocca & M. Filippi

  3. Neuroradiology Service, Hospital of Gallarate, Gallarate, Italy

    G. Minonzio

  4. Department of Neurology, Hospital S. Raffaele, Milan, Italy

    D. Baroncini & G. Comi

Authors
  1. A. Ghezzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. Rocca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Baroncini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Annovazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Zaffaroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Minonzio
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Comi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Filippi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Baroncini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghezzi, A., Rocca, M.A., Baroncini, D. et al. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. J Neurol 260, 327–329 (2013). https://doi.org/10.1007/s00415-012-6744-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-012-6744-7

Keywords

Search

Navigation